Close Menu

NEW YORK (GenomeWeb) – Bristol-Myers Squibb and GeneCentric Diagnostics are working together to explore whether GeneCentric's Cancer Subtype Platform can identify translational biomarkers for BMS's cancer immunotherapy Opdivo (nivolumab).

GeneCentric said it has also secured equity funding from BMS that will support the clinical development of its CSP and the build-out of its new laboratory in North Carolina's Research Triangle Park. It didn't disclose the amount of that investment, however.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers uncovered the HIV virus within a tissue sample collected in 1966, the Atlantic reports.

Nature News reports there are a handful of clinical trials underway to evaluate vaginal microbiome seeding of newborns born via caesarian section.

The Washington Post writes that humans may have contributed to the extinction of cave bears some 20,000 years ago.

In PLOS this week: gene variant may protect against trypanosomiasis, GLIS3 role in type 2 diabetes, and more.